Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...

As officials put the change in draft rules for 2026, the incoming president's Medicare agency pick might support it.

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.